NCT07043985

Brief Summary

In this preliminary study, we propose that the intraepidermic injection of vit C can induce quantitative and qualitative modification of the gingival biotype. We also propose that such improvement is lacking of any pathologic transformation when will compare to the hereditary gingival fibromatosis with highlighting the mechanism of fibrous tissue formation. The study aims secondly to provide a detailed explanation for the pathogenesis of HGF.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 3, 2018

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 5, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 6, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

June 17, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

June 29, 2025

Completed
Last Updated

June 29, 2025

Status Verified

June 1, 2025

Enrollment Period

6.8 years

First QC Date

June 17, 2025

Last Update Submit

June 27, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Area percent occupied by connective tissue

    the percent of the tissues occupied by connective tissue only

    7

Secondary Outcomes (1)

  • Density of Collagen bundles

    7

Study Arms (4)

G1 (positive control): 5 patients suffering from non-syndromic HGF

EXPERIMENTAL

Gingival bioposy was evaluated

Diagnostic Test: biopsy

G2 (negative control): 5 patients of normal healthy gingival tissue (negative control)

EXPERIMENTAL

normal healthy gingival tissue biopsy

Diagnostic Test: biopsy

received intraepidermic vitamin C injection for non-inflammatory purpose

ACTIVE COMPARATOR

vit C injection for non-inflammatory purpose

Diagnostic Test: biopsy

G4: 5 patients received vitamin C injection for inflammatory purposes

ACTIVE COMPARATOR

vitamin C injection for inflammatory purposes

Diagnostic Test: biopsy

Interventions

biopsyDIAGNOSTIC_TEST

Diagnosis of the HGF and healthy tissues depends on pre-described criteria; gingival overgrowth covering one third of the crown length as a minimum, systemically free, no history of drug uptake causing gingival overgrowth (nifedipine, phenytoin, cyclosporine, oral contraceptive pills). Before sampling, written consents were obtained from all patients. Using light microscope, haematoxylin and eosin (H\&E) stained sections were precisely examined and histopathological features were reported. All specimens were assessed semi-quantitatively, on a graded scale, under ×100 magnification power and a fixed grid for the following parameters. Three to four fields of each gingival specimen were randomly selected. A blinded evaluation was done by two independent observers. If a debate was reported regarding a specimen, a consensus was reached following re-evaluation. The most representative areas were selected to be morphometrically analyzed using Leica QWin 500 analyzer computer system (Germany).

G1 (positive control): 5 patients suffering from non-syndromic HGFG2 (negative control): 5 patients of normal healthy gingival tissue (negative control)G4: 5 patients received vitamin C injection for inflammatory purposesreceived intraepidermic vitamin C injection for non-inflammatory purpose

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • patients diagnosed as HGF
  • patients diagnosed with altered passive eruption who needs excess gingival tissue removal
  • no age or gender predilection

You may not qualify if:

  • patienst undertaken drugs cause gingival enlargment
  • prednent and lactating mothers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Entertainment Area, Badr City, Cairo, Egypt

Cairo, Egypt

Location

MeSH Terms

Interventions

Biopsy

Intervention Hierarchy (Ancestors)

CytodiagnosisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisSpecimen HandlingDiagnostic Techniques, SurgicalSurgical Procedures, OperativeInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor

Study Record Dates

First Submitted

June 17, 2025

First Posted

June 29, 2025

Study Start

January 3, 2018

Primary Completion

November 5, 2024

Study Completion

May 6, 2025

Last Updated

June 29, 2025

Record last verified: 2025-06

Locations